Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Imfinzi
Descriptions
Durvalumab injection is used in combination with platinum-containing chemotherapy before surgery and then used alone after surgery in patients with non-small cell lung cancer (NSCLC) which can be removed by surgery and do not have an abnormal EGFR or ALK gene. It is also used alone to treat NSCLC that has not spread and cannot be removed by surgery in patients who have received other cancer medicines (eg, platinum) and radiation treatment for their NSCLC. It is also used in combination with tremelimumab-actl to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body in patients whose tumors do not have an abnormal EGFR or ALK gene. This medicine is also used in combination with etoposide and either carboplatin or cisplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab injection is also used in combination with other cancer medicines (eg, gemcitabine, cisplatin) to treat biliary tract cancer (BTC) that has spread to nearby tissues or to other parts of the body.
Durvalumab injection is also used in combination with tremelimumab-actl to treat liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).
Durvalumab injection is also used alone or in combination with other cancer medicines (eg, carboplatin and paclitaxel) to treat mismatch repair deficient (dMMR) advanced endometrial cancer (cancer of the lining of the uterus or womb) that has spread or has come back.
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.